HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Global Institution for Collaborative Research and Education : GI-CoRE >
Peer-reviewed Journal Articles, etc >

Clinical Evaluation of QuickNaviTM-Ebola in the 2018 Outbreak of Ebola Virus Disease in the Democratic Republic of the Congo

This item is licensed under:Creative Commons Attribution 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL: https://doi.org/10.3390/v11070589


Title: Clinical Evaluation of QuickNaviTM-Ebola in the 2018 Outbreak of Ebola Virus Disease in the Democratic Republic of the Congo
Authors: Makiala, Sheila Browse this author
Mukadi, Daniel Browse this author
De Weggheleire, Anja Browse this author
Muramatsu, Shino Browse this author
Kato, Daisuke Browse this author
Inano, Koichi Browse this author
Gondaira, Fumio Browse this author
Kajihara, Masahiro Browse this author →KAKEN DB
Yoshida, Reiko Browse this author →KAKEN DB
Changula, Katendi Browse this author
Mweene, Aaron Browse this author
Mbala-Kingebeni, Placide Browse this author
Muyembe-Tamfum, Jean-Jacques Browse this author
Masumu, Justin Browse this author
Ahuka, Steve Browse this author
Takada, Ayato Browse this author →KAKEN DB
Keywords: Ebola virus
EVD
rapid diagnostic test
immunochromatography
QuickNavi
DRC
Issue Date: Jul-2019
Publisher: MDPI
Journal Title: Viruses
Volume: 11
Issue: 7
Start Page: 589
Publisher DOI: 10.3390/v11070589
PMID: 31261668
Abstract: The recent large outbreaks of Ebola virus disease (EVD) in West Africa and the Democratic Republic of the Congo (DRC) have highlighted the need for rapid diagnostic tests to control this disease. In this study, we clinically evaluated a previously developed immunochromatography-based kit, QuickNavi(TM)-Ebola. During the 2018 outbreaks in DRC, 928 blood samples from EVD-suspected cases were tested with QuickNavi(TM)-Ebola and the WHO-approved GeneXpert. The sensitivity and specificity of QuickNavi(TM)-Ebola, estimated by comparing it to GeneXpert-confirmed cases, were 85% (68/80) and 99.8% (846/848), respectively. These results indicate the practical reliability of QuickNavi(TM)-Ebola for point-of-care diagnosis of EVD.
Rights: © 2019 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).
https://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/75467
Appears in Collections:人獣共通感染症国際共同研究所 (International Institute for Zoonosis Control) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
国際連携研究教育局 : GI-CoRE (Global Institution for Collaborative Research and Education : GI-CoRE) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University